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Abstract
Background: Hepatitis C virus infection is highly prevalent among people who inject drugs. Opioid substitution
therapy, the standard treatment for opioid dependence, provides an excellent opportunity for the treatment of
hepatitis C virus infection due to the close and regular contact between patients and clinicians. However, there is
little research on the impact of opioid substitution therapy on the prevalence of the hepatitis C virus at a national
level. This paper describes the protocol for the Epidemiology of Hepatitis C Virus Infection among People Receiving
Opioid Substitution Therapy (ECHO) study. The aim of this study is to estimate the national prevalence and incidence
of hepatitis C virus infection among people receiving opioid substitution therapy in Germany and to describe factors
associated with hepatitis C treatment uptake and seroconversion.
Methods/Design: An observational, longitudinal, multicentre study is being conducted between 2014 and 2016 in a
representative sample of approximately 2500 people receiving opioid substitution therapy from about 100 clinicians
providing opioid substitution therapy in Germany. Data will be collected during routine patient care and by means of
patient and clinician questionnaires at baseline and 12-month follow-up. Stratified sampling will be performed to
obtain a representative sample of clinicians providing opioid substitution therapy. The strata will be constructed based
on the distribution of the total sample of clinicians providing opioid substitution therapy in Germany according to
German Federal State and the number of patients per clinician.
Discussion: Opioid substitution therapy may be an important strategy to prevent the spread of hepatitis C
virus in opioid dependent populations, but its effectiveness may be diminished by our limited understanding
of factors associated with treatment uptake and seroconversion. The present study will provide important
information for developing strategies to address hepatitis C virus-related disease burden in people receiving
opioid substitution therapy.
Trial registration: ClinicalTrials.gov: NCT02395198
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Background
Injecting drug use is the primary mode of transmission
for hepatitis C virus (HCV) infection in developed coun-
tries [1–3] and accounts for the vast majority of new in-
fections [4, 5]. With up to 90 % of people who inject
drugs (PWID) being HCV-antibody-positive, HCV is
highly prevalent in this target group. Worldwide, 6–15
million drug users are infected with the virus [6]. Opioid
substitution therapy (OST), the standard treatment for
opioid dependence, provides an excellent opportunity
for managing HCV infection due to the close and regu-
lar contact between patients and clinicians. However,
there is little research on the impact of OST on HCV
prevalence and incidence at a national level.
HCV infection is characterized by an asymptomatic
onset and progression, which delays early diagnosis and
therefore treatment. Treating the infection in its early
stages is vital to avoiding long-term complications. Ap-
proximately 15 % of chronic HCV-infected PWID de-
velop liver cirrhosis within 20 years [7] and the burden
of HCV-related morbidity and mortality among PWID is
significant and increasing [8–10]. Infection duration is a
risk factor for accelerated liver disease progression [1]
and the stage of liver disease is, in turn, a predictor for
the success of antiviral treatment [11, 12]. Early diagno-
sis of HCV infection is therefore of utmost importance.
Accordingly, the current guidelines of the Association
of the Scientific Medical Societies in Germany (AWMF)
for the prevention, diagnosis and treatment of HCV in-
fections recommends testing former and active drug
users every 12 months [13]. OST provides optimal con-
ditions for regularly testing and monitoring HCV infec-
tions by virtue of the therapeutic relationship and
routine contact between patients and clinicians. Never-
theless, recent data from a convenience sample of nearly
600 OST clinicians in Germany demonstrated limited
implementation of the AMWF guidelines, particularly in
small OST centres, with only two-thirds of the centres
regularly testing patients’ HCV status [14].
In 2011–2012, HCV antibody levels among national
samples of PWID in Europe varied from 19 to 84 %,
with 7 of 11 countries reporting prevalence rates higher
than 50 % [15]. Although no national data is available
for Germany, subnational coverage in 2011 suggests a
high prevalence of HCV, with 56 % of PWID in Berlin
having ever been infected with HCV and 71.6 % in the
city of Essen [16, 17]. Cohort studies provide some evi-
dence for the effectiveness of OST in reducing HCV in-
fections [18, 19]. Also model projections show that OST
can reduce HCV prevalence if its coverage is increased
sufficiently, however these reductions can be modest
and require long-term coverage [20–22]. Real-life data
on the effect of OST on HCV prevalence at a national
level is lacking.
Despite growing evidence that PWID can successfully
be treated for HCV [23], treatment uptake varies consid-
erably between countries, from 0 to 64 % [24–26]. There
are various barriers to HCV treatment initiation, in-
cluding fears of low efficacy and adverse side effects
among drug users, as well as concerns of low adher-
ence and perceived risk of reinfection among clini-
cians [14, 27–29]. Yet our understanding of factors
influencing HCV treatment uptake in OST is limited, as
many of these studies have been conducted in populations
of drug users rather than OST patients, using convenience
samples and not representative national samples.
Moreover, the findings are based on the old HCV
treatment regimen with interferon as opposed to newer
treatments with direct-acting antivirals (DAA) without
interferon. Concerns have been raised that drug users
may become careless in safe injection practices if they
are aware of the high success rate and few side effects of
the new HCV therapy [30], thereby leading to higher re-
infection rates. With the impending interferon-free era
of HCV therapy, it is important to re-examine factors in-
fluencing treatment uptake and seroconversion to in-
form public health strategies.
The aim of the Epidemiology of Hepatitis C Virus
Infection among People Receiving Opioid Substitution
Therapy (ECHO) study is to estimate the national
prevalence and incidence of HCV infection among OST
patients in Germany and to examine factors associated
with HCV treatment uptake and seroconversion.
Methods/Design
Study design
ECHO is a non-interventional, observational, longitu-
dinal study being conducted between 2014 and 2016 in a
large representative sample of approximately 2500 OST
patients from about 100 OST clinicians across Germany.
Data is collected during routine patient care and from
questionnaires administered to patients and clinicians.
At baseline, we examine OST patients’ HCV status to
assess HCV prevalence. Also the rate of HCV treatment
uptake among OST patients and factors associated with
treatment uptake are examined. Patients that are HCV
negative at baseline or started HCV treatment up to
12 months prior to baseline are followed up after
12 months to assess the HCV incidence rate, factors in-
fluencing seroconversion, and (if applicable) the course
of HCV treatment (e.g., treatment outcome, side effects).
At both baseline and follow-up, the HCV status will be
recorded from the participant’s chart. Clinicians are
reminded of the HCV treatment guidelines in Germany,
which recommend yearly HCV testing in this high-risk
population, to encourage them to perform HCV anti-
body and/ or HCV RNA testing through the standard of
care within the clinics. The study duration is either 1
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day or 12 months depending on whether participants
take part in the follow-up. Patient recruitment takes
place over 12 months, data collection over 18 months,
and the total length of the study is 27 months.
Participants
Eligibility criteria
Study participants include patients and their clinicians.
Clinicians are recruited first and must:
 Meet the minimum qualification requirements for
addiction therapy in accordance with the Ordinance
on the Prescription, Dispensing and Proof of the
Disposition of Narcotic Drugs (BtMVV) as defined
by the Chamber of Physicians
 Currently provide OST to 4 or more patients
 Have provided written informed consent
Patients recruited from the consenting clinicians must
meet the following criteria:
 Diagnosed opioid dependence according to the
International Statistical Classification of Diseases
and Related Health Problems, 10th revision (ICD-10;
[31])
 Currently in OST
 Minimum age 18
 No severe mental impairment
 Sufficient German reading and writing skills
 Written informed consent
In Germany, clinicians that do not meet the require-
ments for addiction therapy in accordance with the
BtMVV are allowed to provide OST to a maximum of
three patients under the supervision of a clinician (con-
sultant) meeting the minimum qualification require-
ments for addiction therapy. We exclude all clinicians
with less than four OST patients to ensure that only cli-
nicians with a qualification for addiction therapy are in-
cluded in the study.
Sample size
The sample size calculation is based on the primary out-
come variable of HCV incidence among OST patients.
The literature reports an HCV incidence of 2–4 per 100
person-years in this target group [32, 33]. For a sample
size of (at least) 32 patients with HCV seroconversion
and an observation period of 1 year, 800 HCV antibody-
negative patients are needed as an initial sample size.
Based on previous literature [34], we assume an HCV
antibody prevalence of about 68 % among OST patients
in Germany. Therefore a sample size of 2500 patients is
needed (32 % corresponds to N = 800).
Recruitment
Obtaining a representative sample of OST patients is es-
sential in determining the HCV prevalence and inci-
dence among OST patients at a national level.
Clinician recruitment
In Germany, all clinicians who prescribe opioid substitu-
tion medication are registered in the national Substitu-
tion Register, a database maintained by the Federal
Opium Agency of the Federal Institute for Drugs and
Medical Devices (Bundesinstitut für Arzneimittel und
Medizinprodukte, BfArM). In 2013, the Substitution
Register counted 2691 clinicians prescribing opioid sub-
stitution medication. Information about clinicians in the
Substitution Register is unavailable to the public. To en-
sure that all OST clinicians in Germany are considered
in the present study, study invitations were sent to all
substitution medication prescribing clinicians registered
in the database of the National Association of Statutory
Health Insurance Physicians – in German “Kassenärz-
tliche Bundesvereinigung (KBV)”. The KBV mailed the
invitations on our behalf; 524 responses were received,
of which 100 were excluded because they did not pro-
vide written informed consent, 42 because clinicians did
not currently provide OST, and 63 because they treated
three or less patients at the time, leaving 319 clinicians
for sampling.
Sampling method
Official data on the distribution of OST clinicians in
Germany (as of 1.07.2013) was obtained from the Substi-
tution Register. This data was stratified according to
German Federal State (GFS; in German “Bundesland”)
and the number of patients each clinician was treating
(Patients Per Clinician, PPC), the latter consisting of
four self-defined categories: (I) 4 – 10 PPC, (II) 11 – 40
PPC, (III) 41 – 80 PPC, (IV) 80 or more PPC. When cli-
nicians replied to the study invitation, they were asked
to indicate the number of OST patients they attend to,
in order to be allocated to a PPC category. Implausible
PPC values were identified and corrected in consultation
with the corresponding clinician.
Stratified random sampling was performed to preserve
the strata proportions of the population of OST clini-
cians within the sample. The sampling scheme was
structured, based on the distribution of the total sample
of OST clinicians in Germany, according to GFS and
PPC. Using the SPSS Complex Samples procedure, pre-
defined random subsamples for every GFS and PPC cat-
egory were selected from the eligible sample (n = 319).
On 11.07.2014, a representative sample of 88 clinicians
was drawn to arrive at approximately 2500 patients as
planned (Table 1). If clinicians drop out of the study, par-
ticipants will be re-recruited to meet the representativeness
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criteria. If several clinicians meet the criteria, SPSS will be
used to draw one at random, and if no more clinicians
meet the criteria, they will be drawn from the nearest PPC
category rather than a different GFS to maintain national
representativeness.
Patient recruitment
Patients of participating clinicians are included in the
study if they fulfil the eligibility criteria. To avoid clini-
cians with a large number of OST patients from domin-
ating the study sample, a maximum of 60 patients per
clinician is employed. Thus for each clinician with more
than 60 patients, ECHO-study research staff draws a
random sample of 60 patients.
Procedure
Once a representative sample of OST clinicians is drawn,
written informed consent and coded patient lists are
obtained from all clinicians. The codes consist of pa-
tients’ initials, date of birth and gender and are used to
identify questionnaires when they are sent back to the
research centre. Clinicians also indicate which patients
started a course of HCV treatment up to 12 months
prior to baseline, so that the research staff can send the
follow-up questionnaires to the correct patients. If clini-
cians have more than 60 PPC, research staff draws 60
patients as described above and sends the lists of
selected patients back to the clinicians.
Next, study materials are sent and explained to partici-
pating clinicians. Data collection begins after patients
provide written informed consent. The follow-up
phase starts 12 months after study initiation, which
may be a different point in time for each patient. In
case clinicians do not provide written informed con-
sent, stop communicating to the research staff, or do
not collect data, ECHO-study research staff will try
to communicate with OST clinicians to understand
the reason for their inactivity (e.g., they forgot about
the study). If these difficulties are not resolved, the
clinician will be excluded and another clinician will
be recruited according to the same representativeness
criteria.
Monitoring framework and quality of data
A 2-level monitoring framework is implemented to im-
prove the quality of data. Monitoring level 1 ensures
data completeness. Before data collection begins,
ECHO-study research staff briefs clinicians and medical
assistants on the study process, explains the material,
and trains them in proper documentation. Throughout
the study, research staff stays in contact with clinicians
and medical staff via telephone calls and personal visits
to answer any questions and to ensure participation and
complete documentation. Clinicians and medical assis-
tants are responsible for complete and accurate data col-
lection, because data is gathered during routine patient
care. Research staff checks the data for plausibility and
completeness and may ask clinicians and medical staff to
complete or correct missing or implausible data. Re-
search staff merely has access to pseudonymized data at
this stage.
In monitoring level 2, extended in-house source data
verification (SDV) is conducted to ensure accuracy of re-
corded data. SDV is performed on 20 % of the patient
sample of 25 % of clinicians. The more patients a clin-
ician attends to, the more patients from that clinician
are selected for SDV. Trained staff members that are not
otherwise involved in the ECHO-study make use of an
SDV form and check the data for accuracy. If necessary,
they report back to clinicians to clarify and correct im-
plausible or incorrect data entries in the best possible
Table 1 Distribution of OST clinicians by German Federal State
and patients per clinician
Distribution of OST
clinicians in Germany








German Federal State (GFS) % n %
Baden-Württemberg 13.6 11 12.5
Bayern 9.2 8 9.1
Berlin 6.2 5 5.7
Brandenburg 0.3 1 1.1
Bremen 3.0 3 3.4
Hamburg 4.2 4 4.5
Hessen 9.3 8 9.1
Mecklenburg-Vorpommern 0.6 1 1.1
Niedersachsen 9.9 7 8.0
Nordrhein-Westfalen 32.1 27 30.7
Rheinland-Pfalz 3.1 4 4.5
Saarland 0.8 0 0.0
Sachsen 0.8 2 2.3
Sachsen-Anhalt 1.1 1 1.1
Schleswig-Holstein 4.9 5 5.7
Thüringen 0.9 1 1.1
Total 100.0 88 100.0
Patients per clinician (PPC) % n %
4–10 16.7 13 14.8
11–40 44.1 38 43.2
41–80 26.9 24 27.3
>80 12.3 13 14.8
Total 100.0 88 100.0
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way. All data is stored electronically and safely at the re-
search centre.
Variables
Clinician and patient questionnaires are administered at
baseline. Medical staff can complete parts of the clin-
ician questionnaire, including objective information (e.g.,
HCV diagnostics) but not subjective ratings (e.g., prob-
lem severity in various life areas). Clinicians will
complete the follow-up questionnaire for patients that
started HCV treatment up to 12 months prior to base-
line and for patients that were HCV negative at baseline.
Table 2 provides an overview of all instruments.
Patient questionnaire
A. Sociodemographics Sociodemographic factors in-
clude sex, age, citizenship, cultural background, relation-
ship, children, housing, and employment.
B. Quality of life (QOL) In this self-made questionnaire,
patients rate their satisfaction with 10 life domains (em-
ployment, relationship, family, leisure and social
contacts, finances, housing, physical health, mental well-
being, substitution treatment, coping with addiction) on
a 6-point Likert scale.
C. 12-Item Short Form Health Survey (SF-12) The SF-
12 is a 12-item health-related quality of life (HRQOL)
scale [35] developed to measure functional health and
wellbeing from the patient perspective. Physical and
mental composite scores are calculated.
D. Opiate Treatment Index Health Symptoms Scale
(OTI-HSS) and OTI-HSS-extended The Health Symp-
toms Scale of the OTI [36] is a subjective measure of
physical health, comprising a checklist of 50 symptoms for
women and 48 for men across 8 areas of health in which
opioid users typically experience problems: general (14
items), injection-related (5 items), cardio/respiratory (9
items), genitourinary (4 items), gynaecological (2 items),
musculoskeletal (3 items), neurological (10 items), and
gastrointestinal (5 items). Patients indicate whether they
experienced symptoms during the past 30 days. The total
score is the sum of reported symptoms, with higher scores
indicating poorer health. A sub-sample of patients receives
the OTI-HSS with a self-added 5-point Likert scale con-
cerning symptom burden (1 = not at all; 5 = very strong),
the OTI-HSS-extended.
E. Brief Symptom Inventory-18 (BSI-18) The BSI-18 is
a self-report measure of psychological distress [37]. The
burden of 18 physical and psychological symptoms is
rated on a 5-point Likert scale (1 = not at all; 5 = very
much) with regard to the preceding 7 days and yields 3
sub-scores for depression, anxiety, and somatization, and
an overall Global Severity Index.
F. Infectious diseases: Knowledge, needs, and atti-
tudes This self-made questionnaire is designed to assess
patients’ knowledge of their infectious disease status and
of HCV treatment related services, as well as patient
needs and attitudes toward HCV infections. Specifically,
patients indicate their current infection status (Tubercu-
losis, Human immunodeficiency virus (HIV), Hepatitis
A, B, and C Virus) and time elapsed since the last test.
They indicate which HCV treatment-related services are
offered in their OST practice (4 items) and time elapsed
since they last talked to their clinician about HCV. Fur-
thermore, patients indicate whether they have questions
about HCV (5 items; e.g., ‘Prevention of HCV’), how
strongly they agree with statements (4 items; e.g., ‘It is
important to me to be free of HCV’) and whether state-
ments apply to them (3 items; e.g., ‘My clinician recom-
mended HCV treatment to me’).
Table 2 An overview of instruments used in the patient and
clinician questionnaires
Sections Instruments


































Diagnostics prior to the
recent HCV treatment;
Current HCV status
Note: QOL quality of life, SF-12 12-Item Short Form Health Survey, OTI-HSS
Opiate Treatment Index-Health Scale Score, BSI-18 Brief Symptom Inventory-
18, API-Dm Autonomy Preference Index - German modified version, ZAPA
Satisfaction in Outpatient Care – Patient Participation, CGI Clinical Global
Impression, GAF Global Assessment of Functioning
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G. HCV Treatment and Treatment Experience Pa-
tients indicate whether they are currently in or plan to
start HCV treatment, and whether they would take up
HCV treatment. Provided they are or have been in HCV
treatment, patients are queried about treatment success,
treatment provider (e.g., their OST clinician), side
effects, and satisfaction with information given in prep-
aration to treatment.
H. Autonomy Preference Index - German modified
version (API-Dm) The API-Dm is a measure of patient
preferences for decision-making and information seeking
[38]. Sub-scales participation preference (4 items) and
information preference (7 items) are rated on a 5-point
Likert scale (1 = very much in favour; 5 = very much
against) and scored separately. The two total scores are
transformed to a range from 0 to 100, with higher scores
corresponding to a higher preference for decision-
making and information seeking.
I. Satisfaction in Outpatient Care – Patient Partici-
pation (ZAPA) The ZAPA is a German scale measuring
satisfaction in outpatient care with a focus on patient
participation (‘Zufriedenheit in der ambulanten Versor-
gung – Schwerpunkt Patientenbeteiligung’, [39]. Three
items (trust in the clinician, satisfaction with information
given, and quality of the treatment) are rated on a 4-
point Likert scale. The fourth item ‘satisfaction with par-
ticipation’ is omitted in the present study, because it is
covered by API-Dm. The ZAPA is administered twice to
assess satisfaction with OST and satisfaction with HCV
treatment.
Clinician questionnaire
A. Sociodemographics Sociodemographic factors in-
clude patient’s sex, date of birth, height, weight, citizen-
ship, age at onset of opioid dependence.
B. Substitution treatment OST items comprise date of
OST initiation in the present clinic, whether the patient
is in OST for the first time, and current substitution
medication and dose.
C. HCV diagnostic and treatment Patient’s most recent
anti-HCV test and HCV-RNA test results (including
viral load, HCV genotype(−subtype), and duration of
chronic HCV infection) and dates of test results are re-
corded from the participant’s chart. Clinicians are
reminded of the HCV treatment guidelines in Germany,
which recommend yearly HCV testing in this high-risk
population. Further, clinicians report patient’s past re-
ceipt of HCV treatment, treatment start and end date,
treatment outcome and, if applicable, reasons for treat-
ment termination.
D. Somatic and psychiatric diseases Patients’ health
over the past 6 months is assessed by means of a checklist
of somatic diseases (Hepatitis B virus (HBV), HIV, Tuber-
culosis, Chronic obstructive pulmonary (COPD), or
Other) and psychiatric disorders or symptoms (Depres-
sion, Anxiety, Psychotic disorder/symptoms, Posttrau-
matic stress disorder (PTSD), Psychopharmacological
treatment, or Other).
E. Consumption of substances Recent consumption of
cocaine, benzodiazepines, heroin, buprenorphine, am-
phetamine and cannabis is examined using the last three
urine sample results.
F. Problem severity in life areas Clinicians provide a
subjective evaluation of patient’s current problem sever-
ity in various life areas. Twelve life domains (consump-
tion of illegal drugs, consumption of non-prescribed
medication, alcohol consumption, physical health, men-
tal wellbeing, housing, partnership or family, friends,
leisure, employment or education, finances, legal situ-
ation) are rated on a 3-point Likert scale (1 = no prob-
lem, 2 = small problem, 3 = large problem).
G. Clinical Global Impression (CGI) scale The present
study uses a shortened, adjusted version of the CGI scale
[40]. Clinicians estimate the current severity of patients’
mental illness and the degree of improvement since the
start of OST on a 7-point Likert scale; the two items do
not yield a global score.
H. Global Assessment of Functioning (GAF) scale The
GAF Scale [41] is an observer-rated single-item rating
of functioning. Patients’ psychological, social and oc-
cupational functioning during the past 12 months is
assessed on a mental health-illness continuum from
100 to 0 (100 – 91 =No Symptoms; 10 – 1 = Persistent
Danger or Non-functionality).
Clinician questionnaire (follow-up)
A. Recent HCV treatment We examine the course of
HCV treatment, which started up to 12 months prior to
study baseline: Start and end date of the course of HCV
treatment, treatment outcome, whether the patient com-
pleted treatment regularly or terminated treatment early,
and, if applicable, reasons for terminating treatment.
Furthermore, test results (viral load) of the last HCV-
RNA test prior to HCV treatment and of the most re-
cent HCV-RNA test post-treatment; whether the patient
experienced clinically relevant complications due to
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leukopenia, thrombocytopenia, anaemia, or other HCV
treatment side effects; type of HCV medication; and ac-
companying medication (antiretroviral therapy (HIV),
benzodiazepine, antidepressants, other psychotropics).
B. Diagnostics prior to the recent HCV treatment
HCV genotype and subtype, duration of the chronic
HCV infection, degree of fibrosis, and whether the pa-
tient had received HCV treatment before.
C. Current HCV status The current HCV status is re-
corded from the participant’s chart. Clinicians are
reminded of the HCV treatment guidelines in Germany,
which recommend yearly HCV testing in this high-risk
population.
Planned statistical analysis
HCV prevalence will be calculated based on data from
all OST patients at baseline. Additionally, RNA confirm-
ation tests will provide an estimate of the distribution of
HCV genotypes and subtypes. To calculate the incidence
rate per person-years, the expected subsample of ap-
proximately 800 HCV seronegative patients (given a
prevalence rate of 68 % anti-HCV seropositive patients,
see ‘Sample Size’) will be observed over the course of
12 months. Factors influencing HCV treatment uptake
(e.g., physical and mental health) and seroconversion
(e.g., concomitant drug use) will be tested by means of
bivariate and multivariate analyses (e.g., logistic regres-
sion) based on the scale levels of the respective variables.
If patients terminate or drop out of OST or no longer
wish to participate in the study, the reasons and circum-
stances will be documented. Dropouts will be analysed
in an attempt to identify possible predictors for an early
end of treatment.
Ethical considerations
Patients in OST are often seen as ‘difficult patients’ due
to comorbidities and cognitive impairments, while OST
clinicians are busy in everyday clinical practice. There-
fore data collection is integrated into routine patient
care to minimize the burden of the study to both pa-
tients and clinicians. Clinicians selected for the study re-
ceive extensive support from research centre staff
throughout the study process, and both patients and cli-
nicians receive adequate remuneration.
Written informed consent is obtained from patients
and clinicians. Patient data is documented in the study
centres (OST practices); ECHO-study research staff only
has access to pseudonymized data and no patient-related
data. A trained staff member who is not otherwise in-
volved in the ECHO study conducts the SDV. Data is
exclusively handled in the research centre and stored
safely in a protected database, which adheres to the legal
data protection regulations. Ethical approval was
granted by the Ethics Committee of the Medical As-
sociation of Hamburg, Ref. PV4603, and by each local
Ethics Committee in Germany.
Discussion
Injecting drug use remains the primary mode of HCV
acquisition in the Western world [42]. Diagnosis, treat-
ment and monitoring of HCV infection among drug
users must be increased and improved in response to
this endemic. OST may be an important strategy in
reducing the rate of HCV infection among drug users,
but evidence for its effectiveness remains weak to date
[18–22]. ECHO will be the first study to provide rep-
resentative data on the prevalence and incidence of
HCV infection among OST patients, as well as factors
associated with HCV treatment uptake and serocon-
version. As such, it will extend the literature by dem-
onstrating the real-life impact of OST on HCV
infection at a national level.
The present study will provide important information
for developing strategies to address HCV-related disease
burden in this population. Specifically, health care re-
search on HCV prevention and harm reduction strat-
egies will benefit from this study’s findings. Furthermore,
the information gained from this project will be essential
for HCV modelling exercises, which can inform health
policy. The data may be used to model projections of
HCV prevalence over the next decades based upon
current levels of HCV treatment.
A better understanding of barriers and facilitators to
HCV treatment uptake and seroconversion among
people receiving OST is important, particularly in light
of the new interferon-free HCV treatment regimens.
New DAA-based regimens have the potential of substan-
tially reducing the prevalence of HCV infection, however
they are very costly and health care providers are reluc-
tant to prescribe them to drug users, who are considered
a high-risk group for reinfection. Knowing what factors
maximize the success of HCV therapy in OST patients
is essential for convincing service providers to offer the
new, effective HCV therapy to people receiving OST.
Beyond our main research questions, we will examine
a range of covariates and associated topics, such as QOL
and shared decision-making. QOL is increasingly ac-
knowledged as an important treatment outcome criter-
ion in OST. Yet most studies merely measure QOL at
the beginning of OST. The ECHO study will be the first
to deliver cross-sectional, representative data on the
QOL for an entire population of patients in OST. Fur-
thermore, patient-centred care is recognized as a meas-
ure to improve health care by empowering patients to be
actively involved in their treatment. Yet this approach is
not applied in OST. ECHO will be one of the first
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studies to explore OST patients’ preferences in shared
decision-making, satisfaction in patient care, and needs
and attitudes concerning treatment.
The present study appears feasible, as we have been
able to draw a clinician sample according to the repre-
sentativeness criteria GFS and PPC up until manuscript
submission, and our monitoring framework appears
effective. While questionnaires are occasionally incom-
plete, the implemented monitoring system is efficient
and ensures complete data sets. We hope this is encour-
aging to researchers in other countries to pursue similar
investigations.
The study has some anticipated limitations. The sam-
ple may be subject to selection bias, as only 319 of 2691
OST clinicians were willing and eligible to take part in
the ECHO study and clinicians have been dropping out
of the study since. Particularly clinicians from small
practices seem unwilling to participate in the present
study. A similar pattern was observed in a study in
which clinicians from small OST centres did not regu-
larly test for HCV infection in patients [14]. The repre-
sentability of the sample may be compromised if too
many clinicians drop out.
Further, the sample size calculation assumes a 1-year
follow-up of all individuals and does not consider poten-
tial dropouts. Incidence estimates may be biased if only a
small sub-sample returns for follow up. However,
Germany has one of the highest retention rates of OST in
the world [43]. The present study will provide first insights
into HCV incidence among OST patients. All potential
limitations will be discussed in following publications.
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